# Tesamorelin: where the fat changed

> Tesamorelin fat studies | Bullish Peptides — Bullish Peptides follows tesamorelin’s visceral and liver-fat results in adults with HIV, the return of fat after stopping and growth-hormone concerns.

A scan can show a change the bathroom scale misses. Tesamorelin’s case depends on fat location, HIV-associated lipodystrophy and continued treatment.

## HIV-associated visceral fat

Visceral fat surrounds organs deep inside the abdomen. It differs from the fat directly under the skin. Tesamorelin’s strongest human evidence concerns adults with HIV-associated lipodystrophy, a disorder of fat distribution. That setting gives the findings their medical meaning.

In [the six-month trial of 50 adults receiving HIV treatment](https://pubmed.ncbi.nlm.nih.gov/25038357/), the treatment effect on visceral-fat area was -42 square centimetres, comparing the changes in the tesamorelin and placebo groups. Liver fat also declined more with tesamorelin. I like how concrete the scan measurement is: it specifies where the change occurred. It cannot be converted into pounds lost or a forecast for ordinary weight gain.

![A layered abdominal teaching model with fat around internal organs](images/abdominal-fat-model.webp)

*An anatomical illustration of abdominal fat locations, with no treatment result depicted.*

## Continuing and stopping treatment

The [52-week programme](https://pubmed.ncbi.nlm.nih.gov/18690162/) began with 273 people receiving tesamorelin and 137 receiving placebo. Continued treatment sustained a -18% change in visceral fat at 52 weeks; fat reaccumulated after treatment stopped. Overall glucose changes during the programme were not clinically significant.

For my optimism, the return of fat is a substantial condition. The benefit can be real while its persistence depends on continued treatment. I weigh a lasting change differently from a change maintained during treatment.

## Pituitary stimulation

Tesamorelin stimulates the pituitary to release the body’s own growth hormone in pulses. Growth hormone then stimulates liver production of IGF-1, a separate growth factor. Those actions distinguish it from the appetite-focused gut-hormone medicines.

In [the brief study of 13 healthy men](https://pubmed.ncbi.nlm.nih.gov/20943777/), two weeks of treatment raised overnight growth hormone and increased IGF-1 by 181 micrograms per litre. Fasting glucose and insulin-stimulated glucose uptake did not change significantly. That is a short hormone-response experiment. The participants’ strength, longevity and long-term cancer risk remain separate questions.

## Pooled findings and safety

A [2026 meta-analysis of five randomised trials](https://pubmed.ncbi.nlm.nih.gov/41545261/) found reductions in visceral fat, liver fat and trunk fat in HIV-associated lipodystrophy, with an increase in lean body mass. Lean mass includes water and organs as well as muscle; an increase leaves strength unresolved.

[LiverTox](https://www.ncbi.nlm.nih.gov/books/NBK548730/) records United States approval in 2010 for excess abdominal fat in adults with HIV-associated lipodystrophy and judges clinically apparent liver injury unlikely. Approval excludes routine obesity treatment and anti-aging claims. Active malignancy is a labelled contraindication. Growth-hormone and IGF-1 stimulation bring longer-term cancer-safety questions, and reassuring average glucose results cannot guarantee unchanged glucose in each person. Tesamorelin is prohibited in sport.

The casual phrase “belly-fat treatment” reaches beyond the HIV-associated lipodystrophy studied here. The trials have a more precise subject, and that subject is already interesting enough.

---

Bullish Peptides is an independent cohort-first literature digest—not a clinic, a peptide counter, or a permission slip to outrun the evidence.